



## COVID-19 Report to Members ~ March 23, 2021

Reports are sent on Tuesdays, unless there's breaking news.

### Virtual Meetings & Education

#### Governor, DHW to discuss vaccines

Governor Little will be making a vaccine announcement on Wednesday, March 24 at 12pm. DHW has rescheduled their weekly vaccine briefing to follow at 12:30p. Access each livestream via these links:

[Governor's announcement](#)

[DHW briefing](#)

### Reimbursement & Policy

#### Hospital reporting update

HHS updated the hospital reporting guidance this week to reflect several changes due to new products being made available to treat COVID. The updated document and related FAQs are available [here](#).

Data fields for the treatment courses of bamlanivimab/etesevimab are now available and will be required beginning April 7. The therapeutic data is required to be reported weekly on Wednesdays.

With the Johnson & Johnson single dose vaccine now available, HHS has made clarifications to the instructions to reflect counts for those receiving that vaccine. The FAQs regarding vaccination reporting have also been updated (beginning on page 17).

Finally, reporting of reuse or extended use of certain PPE is now an optional field for reporting.

#### FEMA funding available

In early February, President Biden announced the federal share of eligible emergency protective measures paid by FEMA would be 100% and would be applicable to costs from January 20, 2020 through September 30, 2021.

FEMA funds can be used by not-for-profit and governmental hospitals to help offset pandemic-related expenses, including facility, equipment, supply, staffing, and wraparound service costs. In addition to meeting eligibility requirements, recipients must focus on using these funds to reach high-risk communities and underserved populations based on the [CDC's Social Vulnerability Index](#). AHA summarized acceptable uses and other details for FEMA funding in this [Special Bulletin](#).

For additional information and assistance, contact [Ben Roerber](#) or [Jarod Dick](#) at the Idaho Office of Emergency Management.

### Quality & Patient Safety

#### Variants addressed in revised therapy treatment info

Revised fact sheets for monoclonal antibody products that address current COVID variants have been released by the FDA. The revised documents include additional information on the susceptibility and potential resistance of the variants to Bamlanivimab, the Bamlanivimab and Etesevimab cocktail, and REGEN-COV (Casirivimab and Imdevimab).

The revisions address the UK (B.1.1.7), South African (B.1.351), Brazilian (P.1), California (B.1.427/B.1.429) and New York (B.1.526) variants. The monoclonal antibody therapies are designed to treat mild to moderate COVID in those at high risk for severe disease and/or hospitalization.

Revised fact sheets:

[Bamlanivimab](#)

[Bamlanivimab and Etesevimab](#)

[REGEN-COV](#) (Casirivimab and Imdevimab)

[Click to get our COVID-19 Updates](#)

Share this email:



[Manage](#) your preferences | [Opt out](#) using TrueRemove™

Got this as a forward? [Sign up](#) to receive our future emails.

View this email [online](#).

615 N. 7th St.  
Boise, ID | 83701 US

This email was sent to .  
To continue receiving our emails, add us to your address book.

emma

[Subscribe](#) to our email list.